|
MONARCH 2: Abemaciclib in combination with fulvestrant in patients with HR+/HER2- advanced breast cancer who progressed on endocrine therapy |
|
|
|
Stock and Other Ownership Interests - Syndax |
Honoraria - Symphony Evolution |
Consulting or Advisory Role - Coherus Biosciences; Peregrine Pharmaceuticals; Radius Health; Symphony Evolution; Taiho Pharmaceutical |
Research Funding - Genentech/Roche (Inst) |
Travel, Accommodations, Expenses - Nektar; Radius Health; Taiho Pharmaceutical |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Research Funding - Chugai Pharma (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - AstraZeneca; Chugai Pharma; Kyowa Hakko Kirin |
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst) |
|
|
Research Funding - Lilly (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Lilly |
|
|
|
Stock and Other Ownership Interests - Lilly |
|
|
|
|
|
|
Stock and Other Ownership Interests - Lilly |
|
|
|
Stock and Other Ownership Interests - Lilly |
|
|
No Relationships to Disclose |